hGH Fragment 176-191
Also called HGH Frag 176-191, Somatropin fragment 176-191
No single human route established in this referenceAnimal / laboratory reference
Research reference
Animal / laboratory study
hGH 176–191 cell-delivery experiment
Peptide in doxorubicin-loaded nanoparticles; no human schedule
Laboratory cell-viability experiments
Habibullah et al., Drug Des Devel Ther (2022) ↗When results may show
hGH Fragment 176-191
Evidence gap- When change was measured
- This exact-fragment paper does not measure human fat loss or establish a visible-results timeline.
- When to assess
- Laboratory cell-viability experiments
- Conditions and limitations
- MCF-7 cancer cells and molecular docking; not human dosing. AOD9604 is a modified sequence, not interchangeable evidence for hGH 176–191. No fat-loss starter or course is supported here.
- When to stop
- The measured study window is not a validated personal quit rule. Do not increase or prolong exposure because an expected result is absent; severe or persistent reactions need prompt clinical review.
Research timing is descriptive, not a promise or personal instruction. A severe or persistent reaction needs prompt clinical review. This is not medical advice.
Modelled level — every day
1× is the peak after a single dose.
- Steady-state peak
- 1.00× single dose
- Time to steady state
- 3hours
- Administrations
- 7/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- Habibullah et al., Drug Des Devel Ther (2022)AOD9604 is a modified sequence, not interchangeable evidence for hGH 176–191. No fat-loss starter or course is supported here.